

Information pursuant to section 125 para. 1 in conjunction with section 125 para. 5 German Stock Corporation Act (Aktiengesetz, AktG) in connection with Art. 4 para. 1, Table 3 of the Annex to Commission Implementing Regulation (EU) 2018/1212 A. Specification of the message 1. Unique identifier of the event Convocation of the Annual General Meeting of BRAIN Biotech AG on March 18, 2025 in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BNN032025oHV 2. Type of message Convocation of the Annual General Meeting in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: NEWM B. Specification of the issuer 1. ISIN DE0005203947 2. Name of issuer **BRAIN Biotech AG** C. Specification of the meeting 1. Date of the General Meeting March 18, 2025 in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250318 2. Time of the General Meeting 10:00 hours (CET) in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 09:00 hours UTC (Coordinated Universal Time) 3. Type of General Meeting Annual General Meeting with physical presence in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: GMET 4. Location of the General Meeting Melibokushalle, Melibokusstraße 10, 64673 Zwingenberg, Germany 5. Record Date (technical record date) March 11, 2025, 24:00 hours (CET) Irrespective of the number of shares held in safe custody

accounts, the right to attend and vote is based on the number of shares registered in the share register on the day



	of the Annual General Meeting. Orders for the transcription of the share register received by the company after the end of the registration deadline up to and including March 17, 2025, will only be processed and taken into account with effect after the Annual General Meeting on March 18, 2025. Technical record date (technical record date) is therefore the end of March 11, 2025. in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250311
6. Uniform Resource Locator (URL)	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
D. Participation in the general meeting	– Physical presence
Method of participation by shareholder	Physical presence (also by proxy)
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: PH
2. Issuer deadline for the notification of participation	Registration of the shareholder for the general meeting in due time: March 11, 2025, 24:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250311, 23:00 hours UTC (Coordinated Universal Time)
3. Issuer deadline for voting	Attendance at the Annual General Meeting in person
	Until the end of voting on the day of the Annual General Meeting (March 18, 2025) in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250318, until the end of voting
D. Participation in the general meeting	- Absentee voting
Method of participation by shareholder	Exercising voting rights by postal voting
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: EV
2. Issuer deadline for the notification of participation	Registration of the shareholder for the general meeting in due time: March 11, 2025, 24:00 hours (CET); time of receipt being decisive



	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250311, 23:00 hours UTC (Coordinated Universal Time)
3. Issuer deadline for voting	By postal sending and via the password-protected Shareholder Portal of the Company at https://www.brain-biotech-group.com/en/investors/annual-general-meeting: until March 17, 2025, 18 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250317, 17:00 hours UTC (Coordinated Universal Time)
D. Participation in the general meeting of the Company	- Issuing authorization and voting instructions to the proxies
Method of participation by shareholder	Exercising voting rights by issuing authorization and voting instructions to the proxies of the Company
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: PX
2. Issuer deadline for the notification of participation	Registration of the shareholder for the general meeting in due time: March 11, 2025, 24:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250311, 23:00 hours UTC (Coordinated Universal Time)
3. Issuer deadline for voting	By submission by post, by email and via the password-protected Shareholder Portal of the Company at https://www.brain-biotech-group.com/en/investors/annual-general-meeting: March 17, 2025, 18:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250317, 17:00 hours UTC (Coordinated Universal Time)
D. Participation in the general meeting - Authorization of third parties	
Method of participation by shareholder	Authorization of third parties to exercise voting and other rights
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: PX



2. Issuer deadline for the notification of participation	Registration of the shareholder for the general meeting in due time: March 11, 2025, 24:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250311, 23:00 hours UTC (Coordinated Universal Time)
3. Issuer deadline for voting	By submission by post, by email and via the password-protected Shareholder Portal of the Company at https://www.brain-biotech-group.com/en/investors/annual-general-meeting: March 17, 2025, 18:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250317, 17:00 hours UTC (Coordinated Universal Time)
E. Agenda - Agenda Item 1	
Unique identifier of the agenda item	1
2. Title of the agenda item	Submission of the adopted separate annual financial statements and of the approved consolidated financial statements of BRAIN Biotech AG for the fiscal year ending 30 September 2024, the separate management report and the Group management report for the fiscal year from 1 October 2023 until 30 September 2024 with the explanatory reports relating to disclosures pursuant to Sections 289a and 315a of the German Commercial Code (HGB), as well as the report by the Supervisory Board for the fiscal year from 1 October 2023 to 30 September 2024
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	None
5. Alternative voting options	N/A
E. Agenda - Agenda Item 2	
Unique identifier of the agenda item	2
2. Title of the agenda item	Resolution concerning the ratification of the actions of the Management Board for the fiscal year from 1 October 2023 to 30 September 2024
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting



4. Vote	Binding vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BV
5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
E. Agenda - Agenda Item 3	
Unique identifier of the agenda item	3
2. Title of the agenda item	Resolution concerning the ratification of the actions of the Supervisory Board for the fiscal year from 1 October 2023 to 30 September 2024
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	Binding vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BV
5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
E. Agenda - Agenda Item 4	
Unique identifier of the agenda item	4
2. Title of the agenda item	Election of the auditor of the separate financial statements and of the auditor of the consolidated financial statements for the fiscal year from 1 October 2024 to 30 September 2025
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	Binding vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BV
5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
E. Agenda - Agenda Item 5	



1. Unique identifier of the agenda item	5 a)
Title of the agenda item	Elections to the Supervisory Board, Dr. Anna C. Eichhorn
2. The of the agenda item	Elections to the supervisory Board, Br. 7 and C. Elemon
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	Binding vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BV
5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
E. Agenda - Agenda Item 5	
1. Unique identifier of the agenda item	5 b)
2. Title of the agenda item	Elections to the Supervisory Board, Stephen Catling
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	Binding vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BV
5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
E. Agenda - Agenda Item 6	
1. Unique identifier of the agenda item	6
2. Title of the agenda item	Resolution concerning the cancellation of the authorization resolution of the Annual General Meeting of 8 March 2023 concerning the issuance of a stock option plan, concerning the reduction of the Conditional Capital 2023 / II, furthermore concerning the authorization to issue a new stock option plan under issuance of stock options with subscription rights to shares in BRAIN Biotech AG, concerning the creation of a Conditional Capital 2025 / I, as well as



	concerning the amendments to the bylaws required for this purpose
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	Binding vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BV
5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
E. Agenda - Agenda Item 7	
1. Unique identifier of the agenda item	7
2. Title of the agenda item	Resolution concerning the extension of the authorization to hold virtual Shareholders' General Meetings and concerning the corresponding amendment to Section 18 (5) of the Company's bylaws
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	Binding vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: BV
5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
E. Agenda - Agenda Item 8	
1. Unique identifier of the agenda item	8
2. Title of the agenda item	Resolution concerning the approval of the Compensation Report
3. Uniform Resource Locator (URL) of the materials	https://www.brain-biotech-group.com/en/investors/annual-general-meeting
4. Vote	Recommendation vote
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: AV



5. Alternative voting options	Vote in favour, vote against, abstention
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: VF, VA, AB
F. Specification of the deadlines reagenda	egarding the exercise of other shareholders rights - Additions to the
1. Object of deadline	Request to add items to the Agenda (section 122 (2) AktG)
2. Applicable issuer deadline	February 15, 2025, 24:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250215, 23:00 hours UTC (Coordinated Universal Time)
F. Specification of the deadlines re Countermotions of shareholders	egarding the exercise of other shareholders rights -
1. Object of deadline	Submission of countermotions of shareholders pursuant to section 126 (1) AktG
2. Applicable issuer deadline	March 03, 2025, 24:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250303, 23:00 hours UTC (Coordinated Universal Time)
F. Specification of the deadlines re proposals by shareholders	egarding the exercise of other shareholders rights - Election
1. Object of deadline	Submission of election proposals by shareholders pursuant to section 127 AktG
2. Applicable issuer deadline	March 03, 2025, 24:00 hours (CET); time of receipt being decisive
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250303, 23:00 hours UTC (Coordinated Universal Time)
F. Right to information pursuant t	o Section 131 Stock Corporation Act
1. Object of deadline	Right to obtain information at the Annual General Meeting
2. Applicable issuer deadline	March 18, 2025 from the beginning of the Annual General Meeting until the chairman of the meeting restricts the right to obtain information



	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250318 from the beginning of the Annual General Meeting until the chairman of the meeting restricts the right to obtain information
F. Specification of the deadlines regarding the exercise of other shareholders rights - Objection to resolutions of the Annual General Meeting	
1. Object of deadline	Electronic lodging of objections to any resolutions of the Annual General Meeting to the notary's minutes
2. Applicable issuer deadline	On the day of the Annual General Meeting (March 18, 2025), from the beginning of the Annual General Meeting until its closure by the chairperson of the meeting
	in the format pursuant to Commission Implementing Regulation (EU) 2018/1212: 20250318, from the beginning of the Annual General Meeting until its closure by the chairperson of the meeting